How can nanotechnology help membrane vesicle-based cancer immunotherapy development?

Figures & data

Figure 1. Efficacy of DC-mv for tumor rejection in vivo. Mice were vaccinated twice a week intervals with either saline (control), DC-mv from immature DCs (DC-mv_blank), DC-mv carrying antigens from B16 cells (DC-mv_B16) or DC-mv carrying antigens from B16 and LLC cells (DC-mv_B16/LLC). Mice were then injected with B16 (A) or LLC (B) tumor cells 7 d after the last vaccination. DC-mv_B16/LLC vaccine showed highly inhibition effect on tumor growth for both B16 and LLC cell-challenged mice. Adapted from Tian et al.¹⁵

Tian X, Zhu MT, Tian YH, Ramm GA, Zhao YL, Nie GJ. A membrane vesicle-based dual vaccine against melanoma and Lewis lung carcinoma. Biomaterials 2012; 33:6147 - 54; http://dx.doi.org/10.1016/j.biomaterials.2012.05.034; PMID: 22681975

 PubMed Web of Science ®Google Scholar